Please Wait.....
Report
Laryngeal Cancer Therapeutics Market Report and Forecast 2024-2032
Market Report I 2023-10-01 I 160 Pages I EMR Inc.
Laryngeal Cancer Therapeutics Market Report and Forecast 2024-2032
Laryngeal Cancer Therapeutics Market Outlook
The laryngeal cancer therapeutics market size was valued at USD 4.1 billion in 2023, driven by both scientific advancements and demographic shifts across the 7 major regions. The market size is anticipated to grow at a CAGR of 4% during the forecast period of 2024-2032 to achieve a value of USD 5.9 billion by 2032.
Laryngeal Cancer Therapeutics: Introduction
Laryngeal cancer, also known as cancer of the larynx or voice box, is a type of head and neck cancer that begins in the voice box. The larynx, a vital organ for breathing, voice production, and swallowing, is susceptible to cancerous growths, primarily attributed to factors like prolonged tobacco use, excessive alcohol consumption, and certain strains of the human papillomavirus (HPV). The therapeutic approach to laryngeal cancer often hinges on the tumour's location, size, stage, and the patient's overall health.
Key Trends in the Laryngeal Cancer Therapeutics Market
The laryngeal cancer therapeutics market is evolving, shaped by both scientific advancements and demographic shifts. A significant trend is the rise of targeted therapies and immunotherapies. Unlike conventional treatments, these focus on specific molecular targets associated with cancer, minimizing damage to healthy cells. The advent of personalized medicine is revolutionizing treatment paradigms, as therapeutics are increasingly tailored to individual patient's genetic makeup and tumour characteristics. The increased prevalence of risk factors such as tobacco consumption, especially in developing nations, is driving the demand for advanced treatments. Concurrently, there is a growing emphasis on early detection and diagnosis, which can significantly improve treatment outcomes and expand the therapeutic window.
Collaborative research initiatives between academia and the pharmaceutical industry are accelerating drug discovery and development. Moreover, the integration of digital tools and AI in research is hastening the identification of potential drug candidates and optimizing treatment regimens. In essence, the laryngeal cancer therapeutics market is moving towards more precision-based treatments, underpinned by advanced research, heightened awareness, and technological innovations.
Laryngeal Cancer Therapeutics Market Segmentation
Market Breakup by Product Type
- Biologics
- Small Molecules
Market Breakup by Treatment Type
- Radiation Therapy
- Chemotherapy
- Immunotherapy
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Topical
Market Breakup by Stage
- Stage 0
- Stage-I
- Stage-II
- Stage-III
- Stage-IV
Market Breakup by End User
- Hospitals
- Homecare
- Specialty Centres
- Others
Market Breakup by Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
o Germany
o France
o Italy
o Spain
o United Kingdom
- Japan
Laryngeal Cancer Therapeutics Market Overview
The laryngeal cancer therapeutics market is witnessing sustained growth, underpinned by the rising incidence of laryngeal cancer, largely attributed to factors like tobacco use and certain strains of HPV. As the disease garners more attention, there's a noticeable push towards innovative treatments. Targeted therapies and immunotherapies are gaining prominence, offering treatments that are more precise and often accompanied by fewer side effects than conventional methods. The move towards personalized medicine is another notable trend, with treatments increasingly being tailored to an individual's genetic profile and the specific characteristics of their tumours. While developed regions, with their advanced healthcare infrastructures, lead in market share and treatment innovation, developing countries are catching up rapidly, driven by increased healthcare spending and awareness campaigns.
Collaborative efforts between research institutions and pharmaceutical companies are accelerating the pace of drug discovery, while the integration of technology ensures streamlined research and better patient management. In summary, the laryngeal cancer therapeutics market is on an upward trajectory, fuelled by innovative treatments, collaborative research, and an increasing focus on early detection and personalized care.
Laryngeal Cancer Therapeutics Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Johnson & Johnson Private Limited
- Cipla Inc.
- Abbott
- AbbVie Inc.
- Merck KGaA
- Bausch Health Companies Inc.
- Sun Pharmaceutical Industries Ltd
- Aurobindo Pharma
- Lupin
- Hikma Pharmaceuticals PLC
- Amneal Pharmaceuticals LLC
- Pfizer Inc.
- Mylan N.V.
- Bristol-Myers Squibb Company
- GSK plc.
We at Expert Market Research always strive to provide you with the latest information. The numbers in the article are only indicative and may be different from the actual report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Laryngeal Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Laryngeal Cancer Therapeutics Epidemiology Analysis-7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.3.1 Germany Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.3.2 France Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.3.3 Italy Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.3.4 Spain Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Laryngeal Cancer Epidemiology Forecast (2017-2032)
5.4 Japan Laryngeal Cancer Epidemiology Forecast (2017-2032)
6 Laryngeal Cancer Treatment Market Overview - 7MM
6.1 Laryngeal Cancer Treatment Market Historical Value (2017-2023)
6.2 Laryngeal Cancer Treatment Market Forecast Value (2024-2032)
7 Laryngeal Cancer Therapeutics Market Landscape
7.1 Laryngeal Cancer Therapeutics: Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Laryngeal Cancer Therapeutics: Product Landscape
7.2.1 Analysis by Product Type
7.2.2 Analysis by Treatment Type
7.2.3 Analysis by Route of Administration
8 Laryngeal Cancer Therapeutics Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Laryngeal Cancer Therapeutics Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter's Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Laryngeal Cancer Therapeutics Market Segmentation-7MM
11.1 Laryngeal Cancer Therapeutics Market by Product Type
11.1.1 Market Overview
11.1.2 Biologics
11.1.3 Small Molecules
11.2 Laryngeal Cancer Therapeutics Market by Treatment Type
11.2.1 Market Overview
11.2.2 Radiation Therapy
11.2.3 Chemotherapy
11.2.4 Immunotherapy
11.2.5 Others
11.3 Laryngeal Cancer Therapeutics Market by Route of Administration
11.3.1 Market Overview
11.3.2 Oral
11.3.3 Parenteral
11.3.4 Topical
11.4 Laryngeal Cancer Therapeutics Market by Stage
11.4.1 Market Overview
11.4.2 Stage 0
11.4.3 Stage-I
11.4.4 Stage-II
11.4.5 Stage-III
11.4.6 Stage-IV
11.5 Laryngeal Cancer Therapeutics Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Homecare
11.5.4 Specialty Centres
11.5.5 Others
11.6 Laryngeal Cancer Therapeutics Market by Distribution Channel
11.6.1 Market Overview
11.6.2 Hospital Pharmacies
11.6.3 Retail Pharmacies
11.6.4 Online Pharmacies
11.7 Laryngeal Cancer Therapeutics Market by Region
11.7.1 Market Overview
11.7.2 United States
11.7.3 EU-4 and the United Kingdom
11.7.4 Japan
12 United States Laryngeal Cancer Therapeutics Market
12.1 U.S. Laryngeal Cancer Therapeutics Market Historical Size (2017-2024)
12.2 U.S. Laryngeal Cancer Therapeutics Market Forecast Size (2024-2032)
12.3 Market Size by Therapeutic Class
13 EU-5 and the United Kingdom Laryngeal Cancer Therapeutics Market
13.1 EU-5 and the United Kingdom Laryngeal Cancer Therapeutics Market Historical Size (2017-2024)
13.2 EU-5 and the United Kingdom Laryngeal Cancer Therapeutics Market Forecast Size (2024-2032)
13.3 Market Size by Therapeutic Class
14 Japan Laryngeal Cancer Therapeutics Market
14.1 Japan Laryngeal Cancer Therapeutics Market Historical Size (2017-2024)
14.2 Japan Laryngeal Cancer Therapeutics Market Forecast Size (2024-2032)
14.3 Market Size by Therapeutic Class
15 Regulatory Framework
15.1 Regulatory Overview
15.1.1 US FDA
15.1.2 EU EMA
15.1.3 JAPAN PMDA
16 Patent Analysis
16.1 Analysis by Type of Patent
16.2 Analysis by Publication year
16.3 Analysis by Issuing Authority
16.4 Analysis by Patent Age
16.5 Analysis by CPC Analysis
16.6 Analysis by Patent Valuation
16.7 Analysis by Key Players
17 Grants Analysis
17.1 Analysis by year
17.2 Analysis by Amount Awarded
17.3 Analysis by Issuing Authority
17.4 Analysis by Grant Application
17.5 Analysis by Funding Institute
17.6 Analysis by NIH Departments
17.7 Analysis by Recipient Organization
18 Clinical Trials Analysis
18.1 Analysis by Trial Registration Year
18.2 Analysis by Trial Status
18.3 Analysis by Trial Phase
18.4 Analysis by Therapeutic Area
18.5 Analysis by Geography
19 Funding and Investment Analysis
19.1 Analysis by Funding Instances
19.2 Analysis by Type of Funding
19.3 Analysis by Funding Amount
19.4 Analysis by Leading Players
19.5 Analysis by Leading Investors
19.6 Analysis by Geography
20 Partnership and Collaborations Analysis
20.1 Analysis by Partnership Instances
20.2 Analysis by Type of Partnership
20.3 Analysis by Leading Players
20.4 Analysis by Geography
21 Supplier Landscape
21.1 Johnson & Johnson Private Limited
21.1.1 Financial Analysis
21.1.2 Product Portfolio
21.1.3 Demographic Reach and Achievements
21.1.4 Mergers and Acquisitions
21.1.5 Certifications
21.2 Cipla Inc.
21.2.1 Financial Analysis
21.2.2 Product Portfolio
21.2.3 Demographic Reach and Achievements
21.2.4 Mergers and Acquisitions
21.2.5 Certifications
21.3 Abbott
21.3.1 Financial Analysis
21.3.2 Product Portfolio
21.3.3 Demographic Reach and Achievements
21.3.4 Mergers and Acquisitions
21.3.5 Certifications
21.4 AbbVie Inc.
21.4.1 Financial Analysis
21.4.2 Product Portfolio
21.4.3 Demographic Reach and Achievements
21.4.4 Mergers and Acquisitions
21.4.5 Certifications
21.5 Merck KGaA
21.5.1 Financial Analysis
21.5.2 Product Portfolio
21.5.3 Demographic Reach and Achievements
21.5.4 Mergers and Acquisitions
21.5.5 Certifications
21.6 Bausch Health Companies Inc.
21.6.1 Financial Analysis
21.6.2 Product Portfolio
21.6.3 Demographic Reach and Achievements
21.6.4 Mergers and Acquisitions
21.6.5 Certifications
21.7 Sun Pharmaceutical Industries Ltd.
21.7.1 Financial Analysis
21.7.2 Product Portfolio
21.7.3 Demographic Reach and Achievements
21.7.4 Mergers and Acquisitions
21.7.5 Certifications
21.8 Aurobindo Pharma
21.8.1 Financial Analysis
21.8.2 Product Portfolio
21.8.3 Demographic Reach and Achievements
21.8.4 Mergers and Acquisitions
21.8.5 Certifications
21.9 Lupin
21.9.1 Financial Analysis
21.9.2 Product Portfolio
21.9.3 Demographic Reach and Achievements
21.9.4 Mergers and Acquisitions
21.9.5 Certifications
21.10 Hikma Pharmaceuticals PLC
21.10.1 Financial Analysis
21.10.2 Product Portfolio
21.10.3 Demographic Reach and Achievements
21.10.4 Mergers and Acquisitions
21.10.5 Certifications
21.11 Amneal Pharmaceuticals LLC.
21.11.1 Financial Analysis
21.11.2 Product Portfolio
21.11.3 Demographic Reach and Achievements
21.11.4 Mergers and Acquisitions
21.11.5 Certifications
21.12 Pfizer Inc.
21.12.1 Financial Analysis
21.12.2 Product Portfolio
21.12.3 Demographic Reach and Achievements
21.12.4 Mergers and Acquisitions
21.12.5 Certifications
21.13 Mylan N.V.
21.13.1 Financial Analysis
21.13.2 Product Portfolio
21.13.3 Demographic Reach and Achievements
21.13.4 Mergers and Acquisitions
21.13.5 Certifications
21.14 Bristol-Myers Squibb Company
21.14.1 Financial Analysis
21.14.2 Product Portfolio
21.14.3 Demographic Reach and Achievements
21.14.4 Mergers and Acquisitions
21.14.5 Certifications
21.15 GSK plc.
21.15.1 Financial Analysis
21.15.2 Product Portfolio
21.15.3 Demographic Reach and Achievements
21.15.4 Mergers and Acquisitions
21.15.5 Certifications
22 Laryngeal Cancer Therapeutics - Distribution Model (Additional Insight)
22.1 Overview
22.2 Potential Distributors
22.3 Key Parameters for Distribution Partner Assessment
23 Key Opinion Leaders (KOL) Insights (Additional Insight)
24 Company Competitiveness Analysis (Additional Insight)
24.1 Very Small Companies
24.2 Small Companies
24.3 Mid-Sized Companies
24.4 Large Companies
24.5 Very Large Companies
25 Payment Methods (Additional Insight)
25.1 Government Funded
25.2 Private Insurance
25.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security